Business Context and Reporting Period
This Form 8-K Current Report was filed by CorMedix Inc. on March 12, 2021, regarding events occurring on March 10, 2021. The filing discloses the execution of a new employment agreement with Elizabeth Masson-Hurlburt, the Company's Executive Vice President and Head of Clinical Operations.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- Annual Base Salary: $315,000
- Target Annual Bonus: Up to 30% of base salary
- Equity Compensation: Annual grants of restricted stock, RSUs, or stock options (amounts determined by the Board)
- Severance (Non-Cause Termination): 9 months of base salary plus prorated bonus and COBRA premium payments
Material Changes
The new agreement replaces a prior employment agreement entered into in March 2018. Key changes include:
- Term: Initial three-year term with automatic successive one-year renewals unless terminated with 90 days' notice.
- Salary Protection: Salary cannot be reduced unless all executive management experiences an equal or greater percentage reduction, with a cap of 25% reduction for Ms. Masson-Hurlburt.
- Non-Compete: A 12-month post-employment restriction on engaging in businesses involving preventive anti-infective products that compete with Neutrolin or taurolidine-containing products.
Guidance, Risks, and Contingencies
The filing contains no financial guidance or outlook. Material contingencies and risks are tied to the employment terms:
- Termination for Cause: Results in forfeiture of all unvested equity and stock options granted before and after the agreement's effective date.
- Corporate Transaction: Triggers full vesting and exercisability of all equity awards and stock options.
- Release Requirement: Severance benefits are conditioned upon the executive signing a release of claims against the Company and its affiliates.
Investor Verification Checklist
- Review Exhibit 10.1 for the complete text of the Executive Employment Agreement.
- Verify the specific definitions of "Cause" and "Good Reason" to understand termination triggers.
- Confirm the Company's current cash position to assess the ability to fund potential severance obligations (9 months salary + COBRA).
- Monitor future filings for the specific terms and valuation of the annual equity grants.